Another recent review by Rydén reported, with a high quality of evidence, that the risk of venous thromboembolism was higher in tamoxifen users than aromatase inhibitor users in randomised controlled trials.2 Our study agrees with these results but also shows that this may be accounted for by the increased risk in tamoxifen users. Here, CYP19A1 is linked to venous thromboembolism.